Carbocycles

Carbocycles constitute one of the most fundamental and widely represented structural classes in drug discovery. They encompass a broad range of ring sizes and geometries, from the highly strained cyclopropane through saturated five- and six-membered rings to polycyclic and bridged systems such as bicyclo[2.2.2]octane, bicyclo[1.1.1]pentane, and adamantane. The cyclopropyl ring addresses multiple obstacles encountered during drug discovery, including enhancing potency, reducing off-target effects, increasing metabolic stability, increasing brain permeability, decreasing plasma clearance, and enabling conformational restriction of peptide-derived structures to prevent proteolytic hydrolysis. Saturated carbocycles introduce sp³ character into molecular scaffolds, raising the fraction of sp³ carbons in a lead series and reducing molecular planarity, a property increasingly associated with improved solubility, reduced non-specific binding, and a lower likelihood of hERG channel interaction. Replacement of a meta-substituted benzene with a 1,3-disubstituted cyclohexane has been shown to decrease clearance, supporting its incorporation as a metabolic stability strategy in multiparameter optimisation. Bridged bicyclic carbocycles, including bicyclo[1.1.1]pentane (BCP), have attracted particular attention as compact, three-dimensional bioisosteres for para-substituted arenes, delivering improved aqueous solubility and reduced nonspecific binding without the metabolic liabilities of aromatic rings. The range of therapeutic applications covered by carbocycle-containing drugs spans cardiovascular disease, oncology, antiviral therapy, CNS disorders, and immunosuppression.

Two commercially transformative drugs illustrate the range of pharmacological roles carbocycles can play. Atorvastatin (Lipitor, Pfizer), once the best-selling drug in history, incorporates multiple phenyl carbocycles that form the basis of its HMG-CoA reductase binding pharmacophore, with three aryl rings orienting critical amide and fluorophenyl substituents for tight active-site engagement. Ticagrelor (Brilinta, AstraZeneca) exemplifies how saturated carbocycles can replace labile ribose sugars in nucleoside-inspired drug design. The ribose unit of the adenosine diphosphate parent scaffold was replaced with a cyclopentyl carbocycle to remove the hydrolytic liability of the sugar, while an appended difluorophenyl cyclopropylamine enhanced P2Y12 receptor affinity. The resulting molecule is a blockbuster oral antiplatelet agent used in acute coronary syndrome worldwide.

Three recent first-in-class approvals demonstrate carbocycles' continued role in precision oncology and beyond. Nirogacestat (Ogsiveo, SpringWorks Therapeutics), approved by the FDA in November 2023, became the first gamma-secretase inhibitor approved for clinical use and the first therapy specifically approved for desmoid tumours. Its structure features a tetrahydronaphthalene bicarbocyclic core that positions the key pharmacophoric elements within the presenilin active site. Repotrectinib (Augtyro, Bristol-Myers Squibb), approved in 2023 for ROS1-positive non-small cell lung cancer and NTRK-fusion solid tumours, is a next-generation macrocyclic kinase inhibitor whose compact architecture circumvents steric hindrance from resistance mutations by constraining the inhibitor geometry through a phenyl carbocycle embedded within its macrocyclic ring system. Aficamten (Myqorzo, Cytokinetics), FDA-approved in December 2025 for the treatment of symptomatic obstructive hypertrophic cardiomyopathy, was discovered through optimisation of an indoline lead and centres on a chiral (1R)-indane bicarbocyclic core, a fused benzene-cyclopentane system in which the stereodefined sp³ carbon bearing the carboxamide substituent projects the pyrazole pharmacophore into a distinct allosteric site on the cardiac myosin S1 catalytic domain, stabilising a weak actin-binding state and reducing the number of force-generating cross-bridges, with the indane carbocycle providing both the conformational rigidity and the stereochemical presentation required for potency and selectivity over smooth and skeletal muscle isoforms.

Carbocycles have a central and growing role in emerging synthetic methodology. In photochemistry, the visible-light-mediated [2+2] cycloaddition is the most direct route to cyclobutane carbocycles, which appear as cores in natural products and as conformationally rigid fragments in drug candidates. Light-induced [2+2] cycloaddition provides the most straightforward route to cyclobutanes, which are core structures in many natural products, drugs, and bioactive compounds, with recent advances in photocatalytic cage confinement delivering syn-head-to-head diastereomers with high selectivity. For strained, medicinally valuable bicyclic carbocycles, photoredox catalysis has become the dominant synthetic approach. A general and scalable synthesis of bicyclo[1.1.1]pentane halides using only light and [1.1.1]propellane in flow, without catalysts, initiators, or additives, has been reported at milligram, gram, and even kilogram scale, providing a practical platform for generating over 300 BCP-containing compounds for medicinal chemistry.

Electrochemistry has opened parallel routes to small carbocycles. Anodic oxidation of olefins generates electrophilic alkene radical cations that undergo [2+1] cycloaddition with diazo compounds to give cyclopropanes, or [2+2] cycloaddition with styrene derivatives to give cyclobutanes, in a metal- and catalyst-free, scalable process. In organocatalysis, carbocyclic substrates and products are central to some of the field's defining transformations. The Hajos-Parrish-Eder-Sauer-Wiechert reaction, reported in 1971 and catalysed by L-proline, represents one of the earliest examples of enantioselective organocatalysis, using a small carbocycle, cyclopentane-1,3-dione or cyclohexane-1,3-dione, as the reactive partner in an asymmetric intramolecular aldol to generate the bicyclic Wieland-Miescher and Hajos-Parrish ketones as enantiopure building blocks for steroid and terpene synthesis. More recently, the combination of organocatalysis and photoredox catalysis using a Hayashi-Jørgensen diarylprolinol catalyst has enabled the first direct asymmetric synthesis of α-chiral BCPs from simple aldehydes and [1.1.1]propellane in excellent yield and enantiomeric excess. Carbocycles thus occupy a unique position in synthetic chemistry: as targets for emerging methods, as substrates within catalytic cycles, and as pharmacophoric elements that continue to open new space in drug discovery.